XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.

Antineoplastic Agents / therapeutic use Cell Line, Tumor Gene Expression Regulation, Neoplastic / drug effects Humans Hydrazines / therapeutic use Karyopherins / antagonists & inhibitors Lymphoma, Large B-Cell, Diffuse / diagnosis Prognosis Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors Triazoles / therapeutic use Tumor Suppressor Protein p53 / genetics Exportin 1 Protein
BCL2 DLBCL HGBCL MYC Selinexor TP53 mutation XPO1

Journal

Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937

Informations de publication

Date de publication:
04 11 2020
Historique:
received: 19 09 2020
accepted: 22 10 2020
entrez: 5 11 2020
pubmed: 6 11 2020
medline: 8 6 2021
Statut: epublish

Résumé

The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies in high-risk DLBCL. High XPO1 expression (XPO1

Identifiants

DOI: 10.1186/s13045-020-00982-3 PMID: 33148342 PMC: PMC7641823
pubmed: 33148342
doi: 10.1186/s13045-020-00982-3
pii: 10.1186/s13045-020-00982-3
pmc: PMC7641823
doi:

Substances chimiques

Antineoplastic Agents 0
Hydrazines 0
Karyopherins 0
Receptors, Cytoplasmic and Nuclear 0
Triazoles 0
Tumor Suppressor Protein p53 0
selinexor 31TZ62FO8F

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

148

Subventions

Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States

Références

J Hematol Oncol. 2020 Jun 1;13(1):61
pubmed: 32487143
Blood. 2013 Oct 10;122(15):2630-40
pubmed: 23982177
J Hematol Oncol. 2019 Jul 9;12(1):73
pubmed: 31288832
J Hematol Oncol. 2019 Nov 21;12(1):119
pubmed: 31752970
Lancet Haematol. 2020 Jul;7(7):e511-e522
pubmed: 32589977
J Hematol Oncol. 2014 Dec 05;7:85
pubmed: 25476752
Blood. 2013 May 16;121(20):4021-31; quiz 4250
pubmed: 23449635
Blood. 2012 Nov 8;120(19):3986-96
pubmed: 22955915
Int J Clin Exp Pathol. 2018 Dec 01;11(12):5547-5560
pubmed: 31949642
Leukemia. 2012 Sep;26(9):2103-13
pubmed: 22437443
Am Soc Clin Oncol Educ Book. 2017;37:535-546
pubmed: 28561690
Blood Adv. 2020 Feb 11;4(3):586-598
pubmed: 32045477

Auteurs

Manman Deng (M)

Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, School of Medicine, Xiamen, Fujian, China.
Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.

Mingzhi Zhang (M)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Zijun Y Xu-Monette (ZY)

Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.
ORCID: 0000-0002-7615-3949

Lan V Pham (LV)

Phamacyclics, an Abbvie Company, San Francisco, CA, USA.

Alexandar Tzankov (A)

Institute of Pathology, University Hospital Basel, Basel, Switzerland.

Carlo Visco (C)

Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.

Xiaosheng Fang (X)

Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.

Govind Bhagat (G)

Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.

Feng Zhu (F)

Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.

Karen Dybkaer (K)

Aalborg University Hospital, Aalborg, Denmark.

April Chiu (A)

Mayo Clinic, Rochester, MN, USA.

Wayne Tam (W)

Weill Medical College of Cornell University, New York, NY, USA.

Youli Zu (Y)

The Methodist Hospital, Houston, TX, USA.

Eric D Hsi (ED)

Cleveland Clinic, Cleveland, OH, USA.

William W L Choi (WWL)

University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China.

Jooryung Huh (J)

Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.

Maurilio Ponzoni (M)

San Raffaele H. Scientific Institute, Milan, Italy.

Andrés J M Ferreri (AJM)

Odense University Hospital, Odense, Denmark.

Michael B Møller (MB)

Odense University Hospital, Odense, Denmark.

Benjamin M Parsons (BM)

Gundersen Lutheran Health System, La Crosse, WI, USA.

J Han van Krieken (JH)

Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Miguel A Piris (MA)

Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Jane N Winter (JN)

Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Fredrick Hagemeister (F)

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lapo Alinari (L)

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Yong Li (Y)

Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Michael Andreeff (M)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Bing Xu (B)

Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, School of Medicine, Xiamen, Fujian, China. xubingzhangjian@126.com.
Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China. xubingzhangjian@126.com.

Ken H Young (KH)

Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA. ken.young@duke.edu.
Duke Cancer Institute, Durham, NC, USA. ken.young@duke.edu.
ORCID: 0000-0002-5755-8932

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Composés chimiques organiques › Hydrazines › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Caryophérines › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Diagnostic › Pronostic › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › XPO1 expression worsens the prognosis of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › XPO1 expression worsens the prognosis of...